Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by [...] …
Articles by : Shannon Young, Associate Editor/Senior Writer
HHS and Congress should each take long-proposed actions—including a contentious action to curb certain Part B prescribing incentives—to better ensure [...] …
The health center advocacy group behind a proposed 340B program alternative recently slammed the 340B ACCESS Act, saying the newly [...] …
A state Senate-endorsed bill that would have prohibited 340B contract pharmacy restrictions in Rhode Island failed to clear the legislature [...] …
A key West Virginia lawmaker this week hit back against efforts to tie the 340B program to partisan politics, arguing [...] …
The U.S. Supreme Court this week agreed to take on a case that potentially could expand the number of hospitals [...] …
Canadian drugmaker Bausch & Lomb announced last week that, beginning July 1, it will no longer offer 340B discounted products [...] …
A major New York City hospital reported that decreased 340B pharmacy revenue helped drive millions in year-over-year losses in one [...] …
New York lawmakers are expected to leave Albany this week without passing legislation that would bar drug manufacturers and pharmacy [...] …
Swedish biopharmaceutical company Sobi announced this week that beginning July 1 it will implement 340B contract pharmacy restrictions, making the [...] …